StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 4.6
Power Rank trend -> Falling
09/06/2024 16:00:00 EST
10X Genomics Inc (TXG)
Industry: Health Information Services
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, TXG has been trading in a range between $23.49 and $19.65 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
TXG is trading between resistance at $26.29 about 22% to the upside and support at $20.41 -5% to the downside. If it can break above the resistance, it could have some more upside to the next line of resistance at $37.58, about a 74% move. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
10X Genomics Inc $TXG entered a Green zone 34 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $60.33, a potential upside of 180.08% from the recent price of 21.54. The stock is trading 168.8% (potential upside) below its 52 week high of $57.90 and 40.97 % (potential downside) above its 52 week low of $15.28 - based on the recent price.
Company Summary
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
News
| 10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research PLEASANTON, Calif. , Sept. 3, 2024 /PRNewswire/ --Â 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Chromium Xo, a new addition to its fleet of Chromium single cell instruments. Source: PRNewsWire Tue, 03 Sep 2024 16:05:00 -0400 Sentiment: Neutral |
| 10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference PLEASANTON, Calif. , Aug. 22, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, at 10:45 a.m. Source: PRNewsWire Thu, 22 Aug 2024 16:05:00 -0400 Sentiment: Neutral |
| 10x Genomics Cuts 2024 Revenue Outlook as Q2 Sales Miss Estimates Revenue for Q2 2024 rose to $153.1 million, up 4% year-over-year but below management's expectations. Operating expense decreased by 10%, resulting in a narrower net loss of $37.9 million. Source: The Motley Fool Mon, 12 Aug 2024 14:58:24 -0400 Sentiment: Negative |
| 10x Genomics, Inc. (TXG) Q2 2024 Earnings Call Transcript 10x Genomics, Inc. (NASDAQ:TXG ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Cassie Corneau - Director-Investor Relations & Strategic Finance Serge Saxonov - Chief Executive Officer and Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel Tejas Savant - Morgan Stanley Madeline Mollman - Wolfe Research Marta Zaremba - JPMorgan Kyle Boucher - TD Cowen Kyle Mikson - Canaccord Genuity Michael Ryskin - Bank of America Matthew Sykes - Goldman Sachs Matt Larew - William Blair Luke Sergott - Barclays Operator Thank you for standing by. My name is Kayla and I will be your conference operator today. Source: Seeking Alpha Thu, 08 Aug 2024 22:42:09 -0400 Sentiment: Neutral |
| 10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. Source: Zacks Investment Research Thu, 08 Aug 2024 19:01:24 -0400 Sentiment: Neutral |
Technicals 52 Week Hi: 57.9 52 Week Low: 15.28 Beta: 1.848 50 Day MA: 20.1356 200 Day MA: 33.4206 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0 Qtr Revenue Growth YOY: 0.043 Forward PE: 196.0784 Trailing PE: 0